Vincerx Pharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Vincerx Pharma, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $12.10 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2021-11-12
- Vincerx Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-09-30 was -$6.61M.
- Vincerx Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-06-30 was $15.36M.
- Vincerx Pharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-03-31 was $3.35M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2021-09-30 | -$6.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $8.75M derived: sum of 2 quarters · filed 2021-11-12 | $12.10M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $15.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $18.71M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $3.35M 10-Q · filed 2021-05-17 |